賽必妥單抗，Cibisatamab，CAS:2101242-53-7，AntibodySystem Laboratories

貨號：DHC21003

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75488.html

別名：Bispecific, CEA TCB, RG-7802, RO-6958688, CAS: 2101242-53-7

簡介：Cibisatamab (CEA-TCB) 是一種 T 細胞雙特異性抗體，與癌細胞上的癌胚抗原 (CEA) 和 T 細胞上的 CD3 結(jié)合。Cibisatamab (CEA-TCB) 對細胞表面表達中到高水平 CEA 的癌細胞系觸發(fā) T 細胞殺傷。Cibisatamab (CEA-TCB) 可用于結(jié)直腸癌研究。

產(chǎn)品品牌：Antibodysystem

通用名：Cibisatamab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：Bispecific, CEA TCB, RG-7802, RO-6958688

靶點;物種：Human CD66e/CEA/CEACAM5 & CD3E

　　種類：Humanized

　　受體鑒定：IgG1-kappa/lambdawithdomaincrossover

　　CAS: 2101242-53-7

　　存儲條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.等相關(guān)疾病研究。

　　參考文獻：

　　Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers. PMID: 35154495

　　CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. PMID: 30982469

　　Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid. PMID: 34959386

　　Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling. PMID: 33298591

　　Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity. PMID: 34421928